Andrew Arno Purchases 12,500 Shares of OncoCyte Co. Stock
| OCX Stock | USD 2.38 0.07 2.86% |
Slightly above 62% of OncoCyte Corp's investor base is looking to short. The analysis of the overall investor sentiment regarding OncoCyte Corp suggests that many traders are alarmed. OncoCyte Corp's investing sentiment can be driven by a variety of factors including economic data, OncoCyte Corp's earnings reports, geopolitical events, and overall market trends.
OncoCyte |
OncoCyte Co. Director Andrew Arno acquired 12,500 shares of OncoCyte stock in a transaction on Thursday, December 26th. The shares were bought at an average cost of 2.11 per share, with a total value of 26,375.00. Following the completion of the transaction, the director now owns 81,554 shares of the
Read at thelincolnianonline.com
 |
OncoCyte Corp Fundamental Analysis
We analyze OncoCyte Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OncoCyte Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OncoCyte Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
OncoCyte Corp is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
OncoCyte Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OncoCyte Corp stock to make a market-neutral strategy. Peer analysis of OncoCyte Corp could also be used in its relative valuation, which is a method of valuing OncoCyte Corp by comparing valuation metrics with similar companies.
Peers
OncoCyte Corp Related Equities
| DRIO | DarioHealth Corp | 12.86 | ||||
| STIM | Neuronetics | 8.78 | ||||
| BDSX | Biodesix | 4.79 | ||||
| SHC | Sotera Health | 2.40 | ||||
| INBS | Intelligent Bio | 2.19 | ||||
| FONR | Fonar | 1.07 | ||||
| CSTL | Castle Biosciences | 0.04 | ||||
| TRIB | Trinity Biotech | 1.12 | ||||
| SERA | Sera Prognostics | 2.40 | ||||
| BNR | Burning Rock | 2.88 | ||||
| PSNL | Personalis | 3.18 | ||||
| XGN | Exagen | 4.21 | ||||
| PRPO | Precipio | 4.48 | ||||
| ISPC | ISpecimen | 5.00 |
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.